The FDA has approved Lynparza as a first-line treatment after it reduced the risk of disease progression or death by 47 percent in patients.
List view / Grid view
Filter the results
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
A key session opens up the challenges of delivering personalized genetic medicines...
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
18 August 2016 | By The Institute of Cancer Research, London
In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...
Caroline Quentin announced as patron of Coeliac UK, supporting the charity’s campaign to find the undiagnosed half a million
19 March 2015 | By Victoria White
Actress and TV personality, Caroline Quentin has been announced as the new Patron of Coeliac UK, the national Charity for people with coeliac disease, and will support their campaign to improve diagnosis rates which is launched at the start of Coeliac Awareness Week on 11 May 2015.
26 September 2014 | By Sigma-Aldrich
This pharma webinar discusses the decision to generate iPSC disease models to more efficiently and quickly validate two potential lung cancer targets, as well as considerations for undertaking successful cell engineering projects for high-content screening assay development and target validation.